机译:Nivolumab对先前治疗的非小细胞肺癌患者的多西紫杉醇:两年随机,开放标签,第III期试验的两年成果(Checkmate 017和Checkmate 057)
Vanderbilt Ingram Canc Ctr 1301 Med Ctr Dr Ste 1710 Nashville TN 37232 USA;
Sarah Cannon Res Inst Nashville TN USA;
Univ Chicago Chicago IL 60637 USA;
Hosp Madrid Madrid Spain;
Duke Univ Med Ctr Durham NC USA;
Thoraxklin Heidelberg gGmbH Heidelberg Germany;
NN Blokhin Russian Canc Res Ctr Moscow Russia;
Fox Chase Canc Ctr 7701 Burholme Ave Philadelphia PA 19111 USA;
Hosp Univ Vall dHebron Barcelona Spain;
Hosp Univ Virgen Del Rocio Seville Spain;
Inst Marii Sklodowskiej Curie Ctr Onkol Warsaw Poland;
City Hope Natl Med Ctr Duarte CA USA;
Ist Sci Romagnolo Studio &
Cura Tumori IRCCS Meldola Italy;
Robert Bosch Krankenhaus Stuttgart Germany;
OHC Cincinnati OH USA;
Aix Marseille Univ Assistance Publ Hop Marseille Marseille France;
H Lee Moffitt Canc Ctr &
Res Inst Tampa FL USA;
Inst Nacl Cancerol Mexico City DF Mexico;
Leon Berard Lyon France;
Ist Sci Romagnolo Studio &
Cura Tumori IRCCS Meldola Italy;
Mem Sloan Kettering Canc Ctr 1275 York Ave New York NY 10021 USA;
German Ctr Lung Res LungenClin Grosshansdorf Airway Res Ctr North Grosshansdorf Germany;
Mem Sloan Kettering Canc Ctr 1275 York Ave New York NY 10021 USA;
Bristol Myers Squibb Co Princeton NJ USA;
Bristol Myers Squibb Co Princeton NJ USA;
Bristol Myers Squibb Co Princeton NJ USA;
Bristol Myers Squibb Co Princeton NJ USA;
Johns Hopkins Sidney Kimmel Comprehens Canc Ctr Baltimore MD USA;
Univ Duisburg Essen Univ Hosp Essen Germany;
机译:Nivolumab对先前治疗的非小细胞肺癌患者的多西紫杉醇:两年随机,开放标签,第III期试验的两年成果(Checkmate 017和Checkmate 057)
机译:Nivolumab与先前治疗的晚期非小细胞肺癌(Checkmate 017和Checkmate 057)的Docetaxel):肝转移患者的3年更新和结果
机译:Nivolumab Plus inpilemimab与化疗作为高级非小细胞肺癌的一线治疗,具有高肿瘤突变负担:患者报告的结果由随机,开放标签,III期检查培育227试验结果
机译:培美曲塞与多西他赛单药化疗在未接受化疗的老年晚期非小细胞肺癌患者中的作用
机译:表皮生长因子受体酪氨酸激酶抑制剂治疗晚期非小细胞肺癌疗效的预测生物标志物:随机对照试验的系统评价。
机译:在接受过治疗的晚期非小细胞肺癌患者中Nivolumab与多西他赛的比较:两项随机开放标签III期试验(CheckMate 017和CheckMate 057)的两年结果
机译:Nivolumab与多西紫杉醇在主要的中国患者人口中,具有先前治疗的晚期非小细胞肺癌:从随机,开放标签,第3阶段研究的2年随访(Checkmate 078)